<DOC>
	<DOCNO>NCT03103152</DOCNO>
	<brief_summary>To demonstrate acceptability feasibility recruitment randomise chemoprevention study standard ( 300mg ) low dose ( 100mg ) aspirin vs. placebo and/or Vitamin D3 vs. placebo patient enrol Active Surveillance programme prostate cancer .</brief_summary>
	<brief_title>A Study Examine Effectiveness Aspirin and/or Vitamin D3 Prevent Prostate Cancer Progression</brief_title>
	<detailed_description>The PROVENT study randomise , double blind , placebo control feasibility study examine clinical effectiveness aspirin and/or Vitamin D3 prevent disease progression men Active Surveillance prostate cancer The main outcome measure trial rate patient recruitment randomise chemoprevention study men enrol Active Surveillance programme prostate cancer Secondary outcome include response treatment determine serial multi-parametric magnetic resonance imaging ( MRI ) prostate , biochemical disease progression histological disease progression 12 month therapy finally toxicity and/or allergy aspirin Vitamin D3 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Male subject age 16 year estimate life expectancy three year 2 . Willing able provide write informed consent 3 . Corrected serum calcium &lt; 2.65mmol/l 4 . No previous treatment prostate cancer ( include surgery , hormone therapy , radiotherapy , cryotherapy ) 5 . All subject must Magnetic Resonance Imaging ( MRI ) prostate target biopsy lesion identify 6 . Histologically confirm prostate cancer* follow prostate biopsy ( include least 10 core prostate tissue ) men opt Active Surveillance primary cancer therapy . *PROVENT Prostate Cancer Criteria Inclusion : Gleason score 6 7 Clinical radiological stage &lt; T3 Serum PSA ≤15.0 ng/ml Less 10mm cancer single core Patients must undergo multiparametric MRI deem assessable local radiologist , lesion see must undergone target biopsy ( transrectal transperineal ) within 12 month study enrolment . 1 . Previously treat prostate cancer ( include radiotherapy , hormone therapy , brachytherapy surgery ) 2 . Current enrolment investigational drug , device clinical research study participation study within 30 day randomisation 3 . Current daily use aspirin NSAIDs ; daily dietary supplements/medication contain 400 IU ( 10 microgram per day ) Vitamin D3 ; chronic use ( define &gt; 6 month continuous daily use ) either aspirin replacement Vitamin D3 within two year study enrolment 4 . Current previous use 5α reductase inhibitor finasteride dutasteride 5 . Not willing comply procedural requirement protocol include repeat prostate biopsy 6 . Known allergy/sensitivity intolerance aspirin , salicylates NSAIDs e.g . ibuprofen/ naproxen 7 . Prior history gastrointestinal bleeding ulceration , severe dyspepsia inflammatory bowel disease 8 . Haemophilia bleed diatheses 9 . Prior history renal stone disease 10 . Chronic renal disease ( ≥stage 4 ) 11 . Known hypercalcaemia ( correct serum calcium &gt; 2.65 mmol/l ) untreated hyperparathyroidism 12 . Any bowel condition would make repeat transrectal biopsy hazardous difficult perform e.g . rectourethral fistula , prior bowel surgery abdominoperineal resection . 13 . Any malignancy ( nonmelanoma skin cancer ) complete remission five year 14 . Any serious coexistent medical condition would make repeat prostate biopsy hazardous e.g . anticoagulation require continuous administration 15 . Severe Asthma 16 . G6PD deficiency 17 . Preexisting macular degeneration 18 . All contraindication aspirin Vitamin D3 , include concomitant therapy medication may interact aspirin Vitamin D3 ( see section 4.10 ) 19 . Regular consumption alcohol unit great recommended daily limit 34 unit per day ( men )</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Active Surveillance</keyword>
	<keyword>Chemo-prevention</keyword>
</DOC>